Issue Date: August 6, 2012
Challenging Generic Drug Deals
The European Commission last week claimed that patent settlements between the French drug company Servier and several of its generics competitors may be delaying entry of a generic version of the heart drug perindopril in Europe. The accusation is the latest by officials on both sides of the Atlantic involving the so-called pay-for-delay tactic of drug firms to thwart generic drug competition.
The EC lists generic drug manufacturers Teva . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society